By Dr Wendy Winnall - PCFA Research TeamA recent prostate cancer study from Canada has received a lot of publicity. This study measured the risk of ...

Repare Therapeutics shares jumped in premarket trading after the company agreed to sell its polymerase theta ATPase inhibitor to Gilead Sciences for up to $30 million. Shares were 18% higher at $2.57 ...

Gilead agreed to acquire Repare's RP-3467 cancer drug for up to $30 million, boosting Repare's cash and expected shareholder payout.

Flagship Pioneering, a scientific innovation engine for transformative platforms and products, today announced a research program under its strategic collaboration with Pfizer whereby Flagship-founded ...

TLX591-CDx (Illuccix® in approved jurisdictions, 68 Ga-PSMA-11 ): Positive data from Phase 3 study in Chinese patients provides the basis for near-term NDA submission in China.

A Markey Cancer Center study reveals how prostate cancer cells adapt their metabolism to thrive in bone tissue, offering a ...

A University of Kentucky Markey Cancer Center study reveals how prostate cancer cells adapt their metabolism to thrive in ...

What happens if PSA levels start rising after surgery or radiation for prostate cancer? Up to a third of men treated for the disease will eventually confront this problem. If there's no accompanying ...

Scott Adams explained that doctors are working on a plan to move him to a treatment facility for radiation to target a tumor ...

The FDA has granted full approval to rucaparib (Rubraca) for adults with BRCA-mutated metastatic castration-resistant prostate cancer. The decision is based on a confirmatory analysis of a randomized ...

The FDA has granted standard approval to rucaparib (Rubraca) for the treatment of patients with metastatic ...